Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Ventech in connection with their investment in Mindler
Mandate

Vinge has advised Ventech in connection with their investment in Mindler

April 14, 2020

Vinge has advised Ventech, a leading Seed & Series A-focused European venture capital firm, in connection with their investment in Mindler, Sweden’s largest digital service for mental health.

The series A round, which raised EUR 8 million, was led by Ventech and co-led by Schibsted Growth. The funds raised will be used to accelerate Mindler’s European expansion and to reinforce the startup’s organizational growth and platform development.
 
Vinge’s team consisted of Johan Larsson, Maria Dahlin Kolvik, Karl-Hugo Engdahl and Elsie Nassar.

 

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026